258 related articles for article (PubMed ID: 35293326)
21. Role of Janus Kinase inhibitors in rheumatoid arthritis treatment.
Reddy V; Cohen S
Curr Opin Rheumatol; 2021 May; 33(3):300-306. PubMed ID: 33767091
[TBL] [Abstract][Full Text] [Related]
22. [Janus kinase inhibitors].
Witte T
Z Rheumatol; 2022 Mar; 81(2):94-99. PubMed ID: 34820733
[TBL] [Abstract][Full Text] [Related]
23. Comparison of Janus kinase inhibitors in the treatment of rheumatoid arthritis: a systemic literature review.
Jegatheeswaran J; Turk M; Pope JE
Immunotherapy; 2019 Jun; 11(8):737-754. PubMed ID: 30955397
[TBL] [Abstract][Full Text] [Related]
24. Current unmet needs and emerging novel pharmacotherapies in psoriatic arthritis.
Tahir H; Grewal S
Expert Opin Pharmacother; 2022 Mar; 23(4):417-420. PubMed ID: 34787511
[No Abstract] [Full Text] [Related]
25. JAK Inhibitors in Rheumatology: Implications for Paediatric Syndromes?
Kerrigan SA; McInnes IB
Curr Rheumatol Rep; 2018 Nov; 20(12):83. PubMed ID: 30406861
[TBL] [Abstract][Full Text] [Related]
26. Evaluating upadacitinib for the treatment of psoriatic arthritis.
Akpabio A; Adebajo A
Expert Opin Pharmacother; 2022 Feb; 23(2):169-173. PubMed ID: 35014922
[TBL] [Abstract][Full Text] [Related]
27. The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors.
Bechman K; Yates M; Galloway JB
Pharmacol Res; 2019 Sep; 147():104392. PubMed ID: 31401212
[TBL] [Abstract][Full Text] [Related]
28. How to Use Janus Kinase Inhibitors in the Treatment of Rheumatoid Arthritis? A Clinical Assessment of Risks and Benefits.
Alduraibi FK; Singh JA
Curr Rheumatol Rep; 2023 Dec; 25(12):295-306. PubMed ID: 38102522
[TBL] [Abstract][Full Text] [Related]
29. The Emerging Safety Profile of JAK Inhibitors in Rheumatic Diseases.
Singh JA
BioDrugs; 2023 Sep; 37(5):625-635. PubMed ID: 37351790
[TBL] [Abstract][Full Text] [Related]
30. Start RA treatment - Biologics or JAK-inhibitors?
Caporali R; Germinario S; Kacsándi D; Choy E; Szekanecz Z
Autoimmun Rev; 2024 Jan; 23(1):103429. PubMed ID: 37634678
[TBL] [Abstract][Full Text] [Related]
31. Emerging protein kinase inhibitors for the treatment of rheumatoid arthritis.
Palominos PE; Lineburger IB; Xavier RM
Expert Opin Emerg Drugs; 2021 Sep; 26(3):303-321. PubMed ID: 34365877
[TBL] [Abstract][Full Text] [Related]
32. Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis.
Kerschbaumer A; Smolen JS; Dougados M; de Wit M; Primdahl J; McInnes I; van der Heijde D; Baraliakos X; Falzon L; Gossec L
Ann Rheum Dis; 2020 Jun; 79(6):778-786. PubMed ID: 32381564
[TBL] [Abstract][Full Text] [Related]
33. Management of Peripheral Arthritis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations.
Leung YY; Korotaeva TV; Candia L; Pedersen SJ; Bautista Molano W; Ruderman EM; Bisoendial R; Perez-Alamino R; Olsder W; Möller B; Grazio S; Gudu T; Mody GM; Pineda C; Raffayova H; Rohekar S; Goldenstein-Schainberg C; Gutierrez Urena SR; Casasola Vargas JC; Meghnathi B; Prasad R; Richette P; Miranda JRS; Malliotis N; Lindqvist U; Simon D; Ezeonyeji A; Soriano ER; FitzGerald O
J Rheumatol; 2023 Jan; 50(1):119-130. PubMed ID: 36243409
[TBL] [Abstract][Full Text] [Related]
34. JAK inhibitors impair GM-CSF-mediated signaling in innate immune cells.
Fujita Y; Matsuoka N; Temmoku J; Furuya-Yashiro M; Asano T; Sato S; Matsumoto H; Watanabe H; Kozuru H; Yatsuhashi H; Kawakami A; Migita K
BMC Immunol; 2020 Jun; 21(1):35. PubMed ID: 32539713
[TBL] [Abstract][Full Text] [Related]
35. Herpes zoster in patients with inflammatory arthritides or ulcerative colitis treated with tofacitinib, baricitinib or upadacitinib: a systematic review of clinical trials and real-world studies.
Gialouri CG; Moustafa S; Thomas K; Hadziyannis E; Vassilopoulos D
Rheumatol Int; 2023 Mar; 43(3):421-435. PubMed ID: 36635577
[TBL] [Abstract][Full Text] [Related]
36. Patient-related factors influencing the effectiveness and safety of Janus Kinase inhibitors in rheumatoid arthritis: a real-world study.
Martinez-Molina C; Gich I; Diaz-Torné C; Park HS; Feliu A; Vidal S; Corominas H
Sci Rep; 2024 Jan; 14(1):172. PubMed ID: 38168532
[TBL] [Abstract][Full Text] [Related]
37. Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases.
Taylor PC; Choy E; Baraliakos X; Szekanecz Z; Xavier RM; Isaacs JD; Strengholt S; Parmentier JM; Lippe R; Tanaka Y
Rheumatology (Oxford); 2024 Feb; 63(2):298-308. PubMed ID: 37624925
[TBL] [Abstract][Full Text] [Related]
38. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib.
Traves PG; Murray B; Campigotto F; Galien R; Meng A; Di Paolo JA
Ann Rheum Dis; 2021 Jul; 80(7):865-875. PubMed ID: 33741556
[TBL] [Abstract][Full Text] [Related]
39. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement.
Nash P; Kerschbaumer A; Dörner T; Dougados M; Fleischmann RM; Geissler K; McInnes I; Pope JE; van der Heijde D; Stoffer-Marx M; Takeuchi T; Trauner M; Winthrop KL; de Wit M; Aletaha D; Baraliakos X; Boehncke WH; Emery P; Isaacs JD; Kremer J; Lee EB; Maksymowych WP; Voshaar M; Tam LS; Tanaka Y; van den Bosch F; Westhovens R; Xavier R; Smolen JS
Ann Rheum Dis; 2021 Jan; 80(1):71-87. PubMed ID: 33158881
[TBL] [Abstract][Full Text] [Related]
40. Tofacitinib for the treatment of psoriasis and psoriatic arthritis.
Ighani A; Georgakopoulos JR; Yeung J
G Ital Dermatol Venereol; 2020 Aug; 155(4):400-410. PubMed ID: 32348084
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
